CN105055428A - Application of peroxy-ergosterol in preparation of medicament for treating primary liver cancer - Google Patents
Application of peroxy-ergosterol in preparation of medicament for treating primary liver cancer Download PDFInfo
- Publication number
- CN105055428A CN105055428A CN201510583003.7A CN201510583003A CN105055428A CN 105055428 A CN105055428 A CN 105055428A CN 201510583003 A CN201510583003 A CN 201510583003A CN 105055428 A CN105055428 A CN 105055428A
- Authority
- CN
- China
- Prior art keywords
- peroxy
- ergosterol
- medicament
- liver cancer
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of peroxy-ergosterol in preparation of a medicament for treating the primary liver cancer. The application of peroxy-ergosterol in prepartaion of the medicament for treating the primary liver cancer is disclosed for the first time, so that growth and the clone formation ability of liver cancer cell strains can be effectively suppressed; furthermore, the peroxy-ergosterol compound is a compound from natural medicament resources and has the characteristics of low toxicity and high efficiency; a brand-new selection and a concept are provided for the medicament for treating the primary liver cancer at the present.
Description
[technical field]
The present invention relates to a kind of application of peroxy-ergosterol, particularly relate to the application of peroxy-ergosterol in preparation treatment Primary Hepatic cancer drug, belong to natural medicine field.
[background technology]
Primary hepatocarcinoma refers to the malignant tumor originating from liver parenchyma or intrahepatic biliary epithelium cell, comprise bile duct cell mixed type carcinoma in hepatocarcinoma, intrahepatic cholangiocellular carcinoma and hepatocyte regulating liver-QI, primary hepatocarcinoma is one of tumor that the world is the most common and grade malignancy is the highest, sickness rate occupies the 5th, the world in malignant tumor, mortality rate occupies the 3rd, has the new cases of 50-100 ten thousand every year.Primary Hepatic cancer morbidity is high, at present, radiation and chemotherapy is its main Therapeutic Method, but in the process of radiotherapy, chemotherapy, there is digestive tract reaction in various degree in capital, chemicotherapy also often causes the immunosuppressant of tumor patient, accelerates the growth of tumor, makes transfer more rapid and extensive, and with complication common in radiotherapy or after radiotherapy, as: pneumonia, nephritis and proctitis etc., these complication focus on prevention, once occur, are difficult to reverse.Therefore, seek low toxicity, native antigen Diagnosis medicine efficient and with strong points has great importance, can treat timely and effectively, and avoid the best opportunity this medicine being used for other inapplicable hepatocarcinoma and delay treatment.
Peroxy-ergosterol belongs to phytosterin compound, and its full name is 5 α, 8 α-peroxide Ergota steroid-6,22 (E)-diene-3 β-ol (5 α, 8 α-Epidioxyergosta-6,22-dien-3 beta-ol), be extensively present in edible and medical fungi and other funguses.Document is a lot of about the report of its activity, and patent 201410311586.3 discloses peroxy-ergosterol killing and wounding in Hela cancerous cell and has synergism with paclitaxel, can reduce the consumption of paclitaxel, thus reduce its chemical therapy toxic side effect and expense; Patent 200610126091.9 discloses peroxy-ergosterol has obvious inhibitory action to human breast carcinoma MCF-7 and transplanted hepatoma tumor-bearing mice, and does not have harmful effect to immune organ and body weight; Patent 201210233192.1 discloses it and all has significant inhibitory action to malignant breast cancer cells (MT-1), lymphoma cell (Jurkat) and Tumor cells (U87), particularly has killing action to the tumor stem cell of the drug resistance such as cerebroma stem cell; Su Guge etc. (2012) study discovery: the tumor of ergosterol peroxide to H22 tumor-bearing mice has obvious inhibitory action, namely to the inhibitory action of transplanted tumor.
Above-mentioned patent and document are all concentrated and are reported peroxy-ergosterol and have obvious inhibition to dissimilar tumor cell, and hepatocarcinoma is mainly for transplanted hepatoma.Up to now, the purposes that this compound is treated in Primary Hepatic cancer drug in effect and the preparation for primary hepatocarcinoma has no report.
[summary of the invention]
For the problems referred to above, the object of this invention is to provide the application of a kind of peroxy-ergosterol in preparation treatment Primary Hepatic cancer drug, for the existing technical field preparing Primary Hepatic cancer drug provides a kind of new approach.
Technical scheme of the present invention is:
The application of peroxy-ergosterol, is specifically applied to preparation treatment Primary Hepatic cancer drug.
Described treatment Primary Hepatic cancer drug can be prepared into the pharmaceutical preparation being suitable for people's clinical practice at present, as tablet, capsule, granule, injection etc.
Beneficial effect of the present invention is:
1, the present invention is that current Primary Hepatic cancer drug provides a kind of brand-new selection and thinking, has widened the selection field of Primary Hepatic cancer drug, also for the development of this technical field contributes;
2, the present invention makes public for the first time the purposes of peroxy-ergosterol in preparation treatment Primary Hepatic cancer drug, effectively can suppress growth and the clonality of hepatoma cell strain;
3, the compound peroxy-ergosterol in the present invention is the compound deriving from natural pharmaceutical resources, has low toxicity, efficiently characteristic.
[accompanying drawing explanation]
Fig. 1: the growing state of HepG2 cell strain under the effect of variable concentrations peroxy-ergosterol in embodiment 1;
Fig. 2: the growing state of JHH-1 cell strain under the effect of variable concentrations peroxy-ergosterol in embodiment 1;
Fig. 3: the growing state of Snu449 cell strain under the effect of variable concentrations peroxy-ergosterol in embodiment 1;
Fig. 4: HepG2 cell strain growing state in time under the peroxy-ergosterol effect of 23 μMs in embodiment 2;
Fig. 5: the cell clone situation in embodiment 3 in experimental group and matched group.
[detailed description of the invention]
Explain the present invention further below in conjunction with embodiment, but protection scope of the present invention is not by any restriction of specific embodiment.
Embodiment 1 adopts platform phenol blue colouring method assessing compound peroxy-ergosterol to the growth inhibited effect of human hepatoma cell strain
Take the logarithm cell HepG2, JHH-1 and Snu449 of trophophase, with 5 × 10
4concentration be inoculated in 24 orifice plates, after 4 hours adhere-wall culture, adding peroxy-ergosterol makes its final concentration be respectively: 0 μM, 11 μMs, 23 μMs, 35 μMs, 46 μMs and 58 μMs, administration 24 as a child, observe between each concentration that there were significant differences under an electron microscope, stop cultivating, peroxy-ergosterol is evaluated to the growth effect of human hepatoma cell strain with the blue colouring method of platform phenol, HepG2, the growing state of JHH-1 and Snu449 cell strain under the peroxy-ergosterol effect of variable concentrations respectively as Figure 1-3, peroxy-ergosterol is to human hepatoma cell strain HepG2, JHH-1 and Snu449 all has significant inhibitory action.
The embodiment 2 blue dyeing counting method of platform phenol evaluates peroxy-ergosterol different action time of 23 μMs to the impact of human hepatoma cell HepG 2 proliferation effect
Take the logarithm the cell HepG2 of trophophase, with 5 × 10
4concentration be inoculated in 24 orifice plates, after 4 hours adhere-wall culture, add peroxy-ergosterol and make its final concentration be 23 μMs, be designated as experimental group.Meanwhile, setting does not add peroxy-ergosterol is negative control group.Peroxy-ergosterol is evaluated when concentration is 23 μMs with the blue colouring method of platform phenol, along with the prolongation of time, to the growth effect of human hepatoma cell strain HepG2, as shown in Figure 4, peroxy-ergosterol is when its concentration is 23 μMs, along with the prolongation of incubation time, the inhibition of the proliferation function to human hepatoma cell strain HepG2 is also strengthened thereupon.
Embodiment 3 soft agar forms test evaluation peroxy-ergosterol to the impact of the clonality of HepG2 hepatoma carcinoma cell
Prepare 0.66% agarose and be laid in 6 orifice plates, after agarose solidifies, 1000 HepG2 cells being mixed the soft agar of 0.3% with 23 μMs of peroxy-ergosterols, and be added in 6 orifice plates of the soft agar being covered with 0.66%, be designated as experimental group.Simultaneously, if negative control, and be added in 6 orifice plates of the soft agar being covered with 0.66%, be placed in after incubator cultivates 2 weeks, with coomassie brilliant blue staining, the number of cell clones in statistical experiment group and matched group, its result as shown in Figure 5, as seen from the figure, peroxy-ergosterol, when concentration is 23 μMs, has significant inhibitory action to the clonality of HepG2 cell.
Claims (3)
1. the application of peroxy-ergosterol in preparation treatment Primary Hepatic cancer drug.
2. application according to claim 1, is characterized in that, described in be applied as preparation clinical acceptable pharmaceutical preparation.
3. application according to claim 2, is characterized in that, described pharmaceutical preparation is tablet, capsule, granule or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510583003.7A CN105055428A (en) | 2015-09-14 | 2015-09-14 | Application of peroxy-ergosterol in preparation of medicament for treating primary liver cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510583003.7A CN105055428A (en) | 2015-09-14 | 2015-09-14 | Application of peroxy-ergosterol in preparation of medicament for treating primary liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105055428A true CN105055428A (en) | 2015-11-18 |
Family
ID=54485113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510583003.7A Pending CN105055428A (en) | 2015-09-14 | 2015-09-14 | Application of peroxy-ergosterol in preparation of medicament for treating primary liver cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105055428A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108707180A (en) * | 2018-08-08 | 2018-10-26 | 齐齐哈尔医学院 | 3 beta-hydroxy -5 α, 8 α-peroxide androstane -6- alkene -17- (isatin substitution) hydazone derivatives and preparation and application |
| CN109929006A (en) * | 2019-04-17 | 2019-06-25 | 新疆前进荣耀投资有限公司 | The extracting method and application of ergosterol peroxide in Pleurotus ferulae |
| CN111233968A (en) * | 2020-01-20 | 2020-06-05 | 广东药科大学 | Preparation and identification method of ergosterol peroxide |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101012268A (en) * | 2005-12-09 | 2007-08-08 | 包海鹰 | Fasciation naematoloma ligarine extraction, preparing method thereof and use in preparing pharmaceutical for treating tumour |
| CN102764263A (en) * | 2012-07-06 | 2012-11-07 | 广东粤微食用菌技术有限公司 | Application of 5alpha-8alpha-ergosterol peroxide-6,22(E)-diene-3beta-alcohol to preparation of anti-tumor drug |
| CN103239459A (en) * | 2012-02-02 | 2013-08-14 | 北京北大维信生物科技有限公司 | Use of sterol derivative in preparation of medicines for preventing and/or treating and/or adjunctively treating cancers |
| CN103784481A (en) * | 2014-01-27 | 2014-05-14 | 正源堂（天津）生物科技有限公司 | Method for extracting anti-tumor active component from Cordyceps militaris and application of active component |
-
2015
- 2015-09-14 CN CN201510583003.7A patent/CN105055428A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101012268A (en) * | 2005-12-09 | 2007-08-08 | 包海鹰 | Fasciation naematoloma ligarine extraction, preparing method thereof and use in preparing pharmaceutical for treating tumour |
| CN103239459A (en) * | 2012-02-02 | 2013-08-14 | 北京北大维信生物科技有限公司 | Use of sterol derivative in preparation of medicines for preventing and/or treating and/or adjunctively treating cancers |
| CN102764263A (en) * | 2012-07-06 | 2012-11-07 | 广东粤微食用菌技术有限公司 | Application of 5alpha-8alpha-ergosterol peroxide-6,22(E)-diene-3beta-alcohol to preparation of anti-tumor drug |
| CN103784481A (en) * | 2014-01-27 | 2014-05-14 | 正源堂（天津）生物科技有限公司 | Method for extracting anti-tumor active component from Cordyceps militaris and application of active component |
Non-Patent Citations (2)
| Title |
|---|
| TONJOCK R. KINGE等: "Secondary metabolites of oil palm isolates of Ganoderma zonatum Murill. from Cameroon and their cytotoxicity against five human tumour cell lines", 《AFRICAN JOURNAL OF BIOTECHNOLOGY》 * |
| 杨辉等: "组蛋白去乙酰化酶抑制剂联合芬维A胺诱导人肝癌细胞凋亡的研究", 《临床医学工程》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108707180A (en) * | 2018-08-08 | 2018-10-26 | 齐齐哈尔医学院 | 3 beta-hydroxy -5 α, 8 α-peroxide androstane -6- alkene -17- (isatin substitution) hydazone derivatives and preparation and application |
| CN109929006A (en) * | 2019-04-17 | 2019-06-25 | 新疆前进荣耀投资有限公司 | The extracting method and application of ergosterol peroxide in Pleurotus ferulae |
| CN109929006B (en) * | 2019-04-17 | 2022-01-04 | 新疆前进荣耀投资有限公司 | Extraction method and application of ergosterol peroxide in pleurotus ferulae |
| CN111233968A (en) * | 2020-01-20 | 2020-06-05 | 广东药科大学 | Preparation and identification method of ergosterol peroxide |
| CN111233968B (en) * | 2020-01-20 | 2021-05-04 | 广东药科大学 | Preparation and identification method of ergosterol peroxide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106727432A (en) | A kind of Prussian blue analogue nano particle and preparation method and application | |
| CN104398526B (en) | The application of triptolide and Celastrol in antineoplastic is prepared | |
| CN105055428A (en) | Application of peroxy-ergosterol in preparation of medicament for treating primary liver cancer | |
| CN104906558B (en) | The pharmaceutical composition containing ulinastatin for the treatment of cervical cancer | |
| CN100522184C (en) | Extract with anti-tumor and anti-poisonous activity | |
| CN106265760B (en) | Clostridium ghonii tames application of the strain in radiotherapeutic sensitizer is prepared | |
| CN106974908A (en) | Pharmaceutical composition and purposes containing hdac inhibitor and IRE1 inhibitor | |
| CN107007594A (en) | Vitamin C and oxaliplatin are combined the effect in antitumor | |
| CN101831405B (en) | Lung-targeting metastatic human hepatoma cell strain and establishing method thereof | |
| CN105380956A (en) | Medicine composition which is used for treating leukemia and contains idelalisi and application | |
| CN101831404B (en) | Lymph gland targeted metastatic human hepatoma cell strain and establishing method thereof | |
| CN104127427B (en) | A kind of anticancer synergia compositions | |
| CN104398517A (en) | New application of pyrimethamine and medicinal composition for treating for tumor | |
| CN104825512B (en) | A kind of combination medicine for the treatment of tumor | |
| CN113768924B (en) | Composition capable of inhibiting tumor cells and related application thereof | |
| CN107595872A (en) | A kind of pharmaceutical composition for suppressing prostate cancer stem cells and its application | |
| CN104173354B (en) | Can treating cancer pharmaceutical compositions | |
| CN107441076A (en) | A kind of combination medicine for the treatment of cancer | |
| CN106822069A (en) | Applications of the resveratrol oligomer DipG in the medicine for preparing treatment acute myeloid leukaemia | |
| JP2018002709A (en) | Antitumor agent | |
| CN106420693B (en) | Ginsenoside ROApplication in preparation metastases prophylactic agent | |
| CN106366080A (en) | Anti-melanoma compound and application thereof | |
| CN106265704A (en) | The Traditional Chinese Herb combination of a kind of target tumor hypoxia microenvironment application in oncotherapy | |
| CN103417542B (en) | Oral solid preparation for treatment of leukemia and application thereof | |
| Ying et al. | EXPERIMENTAL STUDY ON HERICIUM ERINACEUS POLYSACCHARIDE EFFECT ON THE EXPRESSION OF NF-KB PROTEIN IN MOUSE S180 TUMOR CELLS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151118 |